Treatment of Mycoplasma pneumoniae infection and status and mechanism of macrolide resistance

VernacularTitle:肺炎支原体的感染治疗及对大环内酯类药物的耐药现状和机制
Author: Yun WU ¹ ; Yi LI ; Yali LIU ; Yingchun XU
Author Information

1. 中国医学科学院北京协和医学院研究生院，北京　100730
Keywords: Mycoplasma pneumoniae; Macrolide; Drug resistance mechanisms
From: Chinese Journal of Microbiology and Immunology 2024;44(8):718-726
CountryChina
Language:Chinese
Abstract: Mycoplasma pneumoniae ( Mp) is an important pathogen causing community-acquired pneumonia. Macrolide is the first choice for the treatment of Mycoplasma pneumoniae pneumonia (MPP), while second-line drugs like tetracyclines or quinolones will be considered for pneumonia caused by macrolide-resistant Mycoplasma pneumoniae (MRMP). The isolation rate of MRMP has increased dramatically worldwide. Data from domestic and abroad indicate that MRMP is highly prevalent in Asian regions such as Japan, China, and Korea. The main mechanism of drug resistance in Mp is mutation A2063G of 23S rRNA V. In addition, mutations in the ribosomal protein L4 and L22 genes, ribosomal methylation modifications and the formation of efflux pumps are also significant drug resistance mechanisms. In this study, we summarize the treatment of MPP, the epidemiology of MRMP and the research progress of its mechanisms systematically.